Journal of Inherited Metabolic Disease

, Volume 31, Issue 3, pp 337–349 | Cite as

‘Non-neuronopathic’ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature

  • M. Biegstraaten
  • I. N. van Schaik
  • J. M. F. G. Aerts
  • C. E. M. Hollak


Gaucher disease is a lysosomal storage disorder, which is classically divided into three types. Type I Gaucher disease is differentiated from types II and III disease by the absence of nervous system involvement. However, an increasing number of reports has emerged on neurological manifestations in patients with type I Gaucher disease. Whether a strict division in three different phenotypes is still valid has been the subject of debate. The main objective of this study was to provide scientific arguments whether a distinction between type I (non-neuronopathic) and types II and III (neuronopathic) Gaucher disease should be maintained. We investigated retrospectively a large Dutch cohort of type I Gaucher disease patients for the prevalence of neurological manifestations and provide an overview of the literature on this topic. A diagnosis of a neurological disease was made 34 times in 75 patients. Forty-five patients reported at least one neurological symptom during the median follow-up time of 11 years. The literature search revealed 86 studies in which type I Gaucher disease patients or carriers of a glucocerebrosidase mutation were described with a neurological disease or a condition which is known to be associated with neurological disease. In conclusion, the term non-neuronopathic Gaucher disease does not seem to be an appropriate characterization of type I Gaucher disease. However, the neurological signs and symptoms in type I Gaucher disease are of a totally different kind from and, in the majority of cases, of much less severity than the signs and symptoms associated with types II and III disease Therefore, type I disease should be classified as a separate phenotype.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 351: 1972–1977.PubMedGoogle Scholar
  2. Aharon-Peretz J, Badarny S, Rosenbaum H, Gershoni-Baruch R (2005) Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology 65: 1460–1461.PubMedGoogle Scholar
  3. Airo R, Gabusi G, Guindani M (1993) Gaucher’s disease associated with monoclonal gammapathy of undetermined significance: a case report. Haematologica 78: 129–131.PubMedGoogle Scholar
  4. Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosén I (1999) Prevalence of carpal tunnel syndrome in a general population. JAMA 282: 153–158PubMedGoogle Scholar
  5. Bembi B, Marsala SZ, Sidransky E, et al (2003) Gaucher’s disease with Parkinson’s disease: clinical and pathological aspects. Neurology 61: 99–101.PubMedGoogle Scholar
  6. Benjamin D, Bouer D, Pick AI, Zer M, Dintdman M, Pinkhas J (1978) Peripheral cryoglobulinemic neuropathy in a patient with Gaucher’s disease. Acta Haematol 60: 117–121.PubMedGoogle Scholar
  7. Benjamin D, Joshua H, Djaldetti M, Hazaz B, Pinkhas J (1979) Nonsecretory IgD-kappa multiple myeloma in a patient with Gaucher’s disease. Scand J Haematol 22: 179–184.PubMedGoogle Scholar
  8. Benson M, Brandt K, Cohen A, Cathcart E (1975) Neuropathy, M components, and amyloid. The Lancet 305: 10–12.Google Scholar
  9. Berger LA, Warwick R, Mehta A (2001) Isolated Candida infection of the pterygoid muscles in a patient with Gaucher’s disease. AJR Am J Roentgenol 176: 1332–1333.PubMedGoogle Scholar
  10. Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3635–3668.Google Scholar
  11. Bischoff A, Reutter FW, Wegmann T (1967) Peripheral nervous system diseases in morbus Gaucher. New data based on electron microscopy. Schweiz Med Wochenschr 97: 1139–1146.PubMedGoogle Scholar
  12. Boltshauser EJ, Maria BL (1999) Coexistence of Gaucher disease type 1 and Joubert syndrome. J Med Genet 36: 870–871.PubMedGoogle Scholar
  13. Boot RG, Verhoek M, de Fost M, et al (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103: 33–39.PubMedGoogle Scholar
  14. Brady K, Corash L, Bhargava V (1997) Multiple myeloma arising from monoclonal gammopathy of undetermined significance in a patient with Gaucher’s disease. Arch Pathol Lab Med 121: 1108–1111.PubMedGoogle Scholar
  15. Butora M, Kissling R, Frick P (1989) Bone changes in Gaucher disease. Z Rheumatol 48: 326–330.PubMedGoogle Scholar
  16. Chang-Lo M, Yam LT, Rubenstone AI (1967) Gaucher’s disease. Review of the literature and report of twelve new cases. Am J Med Sci 254: 303–335.PubMedGoogle Scholar
  17. Charrow J, Esplin JA, Gribble TJ, et al (1998) Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158: 1754–1760.PubMedGoogle Scholar
  18. Clark LN, Nicolai A, Afridi S, et al (2005) Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson’s disease in subjects of Jewish ethnicity. Mov Disord 20: 100–103.PubMedGoogle Scholar
  19. Cormand B, Vilageliu L, Burguera JM, et al (1995) Gaucher disease in Spanish patients: analysis of eight mutations. Hum Mutat 5: 303–309.PubMedGoogle Scholar
  20. Cormand B, Grinberg D, Gort L, Chabas A, Vilageliu L (1998) Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. Hum Mutat 11: 295–305.PubMedGoogle Scholar
  21. Costello R, O’Callaghan T, Sebahoun G (2006) Gaucher disease and multiple myeloma. Leuk Lymphoma 47: 1365–1368.PubMedGoogle Scholar
  22. Coyne JD, Lynch T, Cotter P, Kealy WF, Duggan PF (1985) Gaucher’s disease: a case report with coincidental vitamin B12 deficiency anaemia. Ir Med J 78: 254–255.PubMedGoogle Scholar
  23. Davis M, Dorfman J (1961) Gaucher’s disease associated with a cerebral astrocytoma. A case report involving an adult. Am Pract Dig Treat 12: 673–677.PubMedGoogle Scholar
  24. de Fost M, vom Dahl S, Weverling GJ, et al (2006) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36: 53–58.PubMedGoogle Scholar
  25. de la Court A, Breteler MM, Meinardi H, Hauser WA, Hofman A (1996) Prevalence of epilepsy in the elderly: the Rotterdan study. Epilepsia 37: 141–147PubMedGoogle Scholar
  26. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM (2004) Incidence of Parkinson disease in a general population: the Rotterdam study. Neurology 63: 1240–1244.PubMedGoogle Scholar
  27. Delpre G, Stark P, Niv Y (2002) B12 deficiency: not an uncommon genetic-related disorder. Br J Haematol 119: 882–883.PubMedGoogle Scholar
  28. Dikman SH, Goldstein M, Kahn T, Leo MA, Weinreb N (1978) Amyloidosis. An unusual complication of Gaucher’s disease. Arch Pathol Lab Med 102: 460–462.PubMedGoogle Scholar
  29. Dispenzieri A, Kyle RA (2005) Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 18: 673–688.PubMedGoogle Scholar
  30. Eblan MJ, Scholz S, Stubblefield BK, et al (2006a) Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism. Neurosci Lett 404: 163–165.PubMedGoogle Scholar
  31. Eblan MJ, Nguyen J, Ziegler SG, et al (2006b) Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Mov Disord 21: 282–283.PubMedGoogle Scholar
  32. Elstein D, Rosenmann E, Reinus C, Paz J, Altarescu G, Zimran A (2003) Amyloidosis and gastric bleeding in a patient with Gaucher disease. J Clin Gastroenterol 37: 234–237.PubMedGoogle Scholar
  33. Flipo RM, is-Lavignasse C, Cortet B, Chastanet P, Goudemand J, Duquesnoy B (1992) “Spontaneous” hematoma of the psoas in Gaucher’s disease. Rev Med Interne 13: 293–295.PubMedGoogle Scholar
  34. Frankel M, Zimran A, Elstein D (2006) Current perception treshold testing for peripheral neuropathy in type 1 Gaucher disease. Haematologia 9: 264–269.Google Scholar
  35. Garfinkel D, Sidi Y, Ben-Bassat M, Salomon F, Hazaz B, Pinkhas J (1982) Coexistence of Gaucher’s disease and multiple myeloma. Arch Intern Med 142: 2229–2230.PubMedGoogle Scholar
  36. Gielchinsky Y, Elstein D, Green R, et al (2001) High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population. Br J Haematol 115: 707–709.PubMedGoogle Scholar
  37. Goker-Alpan O, Schiffmann R, Park JK, Stubblefield BK, Tayebi N, Sidransky E (2003) Phenotypic continuum in neuronopathic gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr 143: 273–276.PubMedGoogle Scholar
  38. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E (2004) Parkinsonism among Gaucher disease carriers. J Med Genet 41: 937–940.PubMedGoogle Scholar
  39. Goldblatt J, Sacks S, Beighton P (1978) The orthopedic aspects of Gaucher disease. Clin Orthop Relat Res 137: 208–214.PubMedGoogle Scholar
  40. Goldblatt J, Keet P, Dall D (1987) Spinal cord decompression for gaucher’s disease. Neurosurgery 21: 227–230.PubMedGoogle Scholar
  41. Grabowski GA (2005) Recent clinical progress in Gaucher disease. Curr Opin Pediatr 17: 519–524.PubMedGoogle Scholar
  42. Grewal RP, Doppelt SH, Thompson MA, Katz D, Brady RO, Barton NW (1991) Neurologic complications of nonneuronopathic Gaucher’s disease. Arch Neurol 48: 1271–1272.PubMedGoogle Scholar
  43. Guimaraes J, Amaral O, Sa Miranda MC (2003) Adult-onset neuronopathic form of Gaucher’s disease: a case report. Parkinsonism Relat Disord 9: 261–264.PubMedGoogle Scholar
  44. Haan J, Peters WG (1994) Amyloid and peripheral nervous system disease. Clin Neurol Neurosurg 96: 1–9.PubMedGoogle Scholar
  45. Halperin A, Elstein D, Zimran A (2006) Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 36: 426–428.PubMedGoogle Scholar
  46. Halperin A, Elstein D, Zimran A (2007) Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease? Acta Neurol Scand 115: 275–278.PubMedGoogle Scholar
  47. Hamlat A, Saikali S, Lakehal M, Pommereuil M, Morandi X (2004) Cauda equina syndrome due to an intra-dural sacral cyst in type-1 Gaucher disease. Eur Spine J 13: 249–252.PubMedGoogle Scholar
  48. Hanash SM, Rucknagel DL, Heidelberger KP, Radin NS (1978) Primary amyloidosis associated with Gaucher’s disease. Ann Intern Med 89(5 Pt 1): 639–641.PubMedGoogle Scholar
  49. Harder H, Eucker J, Zang C, et al (2000) Coincidence of Gaucher’s disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria. Ann Hematol 79: 640–643.PubMedGoogle Scholar
  50. Hemmer B, Glocker FX, Schumacher M, Deuschl G, Lucking CH (1998) Subacute combined degeneration: clinical, electrophysiological, and magnetic resonance imaging findings. J Neurol Neurosurg Psychiatry 65: 822–827.PubMedGoogle Scholar
  51. Hermann G, Wagner LD, Gendal ES, Ragland RL, Ulin RI (1989) Spinal cord compression in type 1 Gaucher disease. Radiology 170: 147–148.PubMedGoogle Scholar
  52. Hoffmann B, Mayatepek E (2005) Neurological manifestations in lysosomal staorage disorders—from pathology to first therapeutic options. Neuropediatrics 36: 285–289.PubMedGoogle Scholar
  53. Hrebicek M, Zeman J, Musilova J, et al (1996) A case of type I Gaucher disease with cardiopulmonary amyloidosis and chitotriosidase deficiency. Virchows Arch 429: 305–309.PubMedGoogle Scholar
  54. IGPSG (1995) Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in tw Italian regions. I. Prevalence and general characteristics of the sample. Italian General Practitioner Study Group (IGPSG). Neurology 45: 1832–1836.Google Scholar
  55. Inouye SK (1998) Delirium in hospitalized older patients: recognition and risk factors. J Geriatr Psychiatry Neurol 11: 118–125PubMedGoogle Scholar
  56. Itokawa K, Tamura N, Kawai N, Shimazu K, Ishii K (2006) Parkinsonism in type I Gaucher’s disease. Intern Med 45: 1165–1167PubMedGoogle Scholar
  57. Jmoudiak M, Itzchaki M, Hadas-Halpern I, et al (2003) Iliopsoas hematoma in a young patient with type I Gaucher disease. Isr Med Assoc J 5: 673–674.PubMedGoogle Scholar
  58. Kaloterakis A, Filiotou A, Koskinas J, et al (1999) Systemic AL amyloidosis in Gaucher disease. A case report and review of the literature. J Intern Med 246: 587–590.PubMedGoogle Scholar
  59. Kaminsky P, Klein M, Jacob C, Deibener J, Duc M (1995) Biclonal gammapathy in type I Gaucher disease. Presse Med 24: 1400.PubMedGoogle Scholar
  60. Kaplan P, Andersson HC, Kacena KA, Yee JD (2006) The clinical and demographic characteristics of nonneuropathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 160: 603–608.PubMedGoogle Scholar
  61. Katz K, Sabato S, Horev G, Cohen IJ, Yosipovitch Z (1993) Spinal involvement in children and adolescents with Gaucher disease. Spine 18: 332–335.PubMedCrossRefGoogle Scholar
  62. Katz K, Tamary H, Lahav J, Soudry M, Cohen IJ (1999) Increased operative bleeding during orthopaedic surgery in patients with type I Gaucher disease and bone involvement. Bull Hosp Jt Dis 58: 188–190.PubMedGoogle Scholar
  63. King JO (1975) Progressive myoclonic epilepsy due to Gaucher’s disease in an adult. J Neurol Neurosurg Psychiatry 38: 849–854.PubMedGoogle Scholar
  64. Kocher MS, Hall JE (2000) Surgical management of spinal involvement in children and adolescents with Gaucher’s disease. J Pediatr Orthop 20: 383–388.PubMedGoogle Scholar
  65. Kono S, Shirakawa K, Ouchi Y, et al (2007) Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. J Neurol Sci 252: 181–184.PubMedGoogle Scholar
  66. Launer LJ, Terwindt GM, Ferrari MD (1999) The prevalence and characteristics of migraine in a population-based cohort. Neurology 53: 537.PubMedGoogle Scholar
  67. Lesic A, Suvajdzic N, Elezovic I, et al (2006) Iliopsoas haematoma in Gaucher disease. J Inherit Metab Dis 29: 593.PubMedGoogle Scholar
  68. Liel Y, Hausmann MJ, Mozes M (1991) Case report: serendipitous Gaucher’s disease presenting as elevated erythrocyte sedimentation rate due to monoclonal gammopathy. Am J Med Sci 301: 393–394.PubMedGoogle Scholar
  69. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 81: 70–73.PubMedGoogle Scholar
  70. Lyons JC, Scheithauer BW, Ginsburg WW (1982) Gaucher’s disease and glioblastoma multiforme in two siblings: a clinicopathologic study. J Neuropathol Exp Neurol 41: 45–53.PubMedGoogle Scholar
  71. MacDonald M, McCathie M, Faed MJ, et al (1975) Proceedings: Gaucher’s disease with biclonal gammopathy. J Clin Pathol 28: 757.PubMedGoogle Scholar
  72. Machaczka M, Rucinska M, Skotnicki AB, Jurczak W (1999) Parkinson’s syndrome preceding clinical manifestation of Gaucher’s disease. Am J Hematol 61: 216–217.Google Scholar
  73. Marie JP, Tulliez M, Tricottet-Paczinski V, Reynes M, Diebold J (1982) Gaucher’s disease with monoclonal gammopathy. Significance of splenic plasmacytosis. Scand J Haematol 28: 54–58.PubMedGoogle Scholar
  74. Markin RS, Skultety FM (1984) Spinal cord compression secondary to Gaucher’s disease. Surg Neurol 21: 341–346.PubMedGoogle Scholar
  75. Marti GE, Ryan ET, Papadopoulos NM, et al (1988) Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am J Hematol 29: 189–194.PubMedGoogle Scholar
  76. McAlarney T, Pastores GM, Hays AP, Latov N (1995) Antisulfatide antibody and neuropathy in a patient with Gaucher’s disease. Neurology 45: 1622–1623.PubMedGoogle Scholar
  77. McKeran RO, Bradbury P, Taylor D, Stern G (1985) Neurological involvement in type 1 (adult) Gaucher’s disease. J Neurol Neurosurg Psychiatry 48: 172–175.PubMedGoogle Scholar
  78. Melamed E, Cohen C, Soffer D, Lavy S (1975) Central nervous system complication in a patient with chronic Gaucher’s disease. Eur Neurol 13: 167–175.PubMedGoogle Scholar
  79. Mercimek-Mahmutoglu S, Gruber S, Wober Ch, Moser E, Stockler-Ipsiroglu S (2004) Evidence of neurological manifestations in patients with type 1 gaucher disease. J Inherit Metab Dis 27(Supplement 1): 153.Google Scholar
  80. Miller JD, McCluer R, Kanfer JN (1973) Gaucher’s disease: neurologic disorder in adult siblings. Ann Intern Med 78: 883.PubMedGoogle Scholar
  81. Miller W, Lamon JM, Tavassoli M, Longmire R, Beutler E (1982) Multiple myeloma complicating Gaucher’s disease. West J Med 136: 122–128.Google Scholar
  82. Mygland A, Monstad P (2001) Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 8:157–165PubMedGoogle Scholar
  83. Neau P, Mercier P, Bouabdallah K, et al (1993) Une étiologie rare de compression médullaire: la maladie de Gaucher. Rev Med Interne 14: 260–262.PubMedGoogle Scholar
  84. Neil JF, Glew RH, Peters SP (1979a) Familial psychosis and diverse neurologic abnormalities in adult-onset Gaucher’s disease. Arch Neurol 36: 95–99.PubMedGoogle Scholar
  85. Neil JF, Merikangas JR, Glew RH (1979b) EEG findings in adult neuronopathic Gaucher’s disease. Clin Electroencephalogr 10: 198–205.PubMedGoogle Scholar
  86. Neudorfer O, Giladi N, Elstein D, et al (1996) Occurence of Parkinson’s syndrome in type 1 Gaucher disease. Q J Med 89: 691–694.Google Scholar
  87. Orvisky E, Park JK, LaMarca ME, et al (2002) Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab 76: 262–270.PubMedGoogle Scholar
  88. Ott A, Breteler MM, van Harskamp F, et al (1995) Prevalence of Alzheimer’s disease and vascular dementia: association with education. The Rotterdam study. BMJ 310: 970–973.PubMedGoogle Scholar
  89. Pastores GM, Barnett NL, Bathan P, Kolodny EH (2003) A neurological symptom survey of patients with type 1 Gaucher disease. J Inherit Metab Dis 26: 641–645.PubMedGoogle Scholar
  90. Peitersen E (1982) The natural history of Bell’s palsy. Am J Otol 4: 107–111PubMedGoogle Scholar
  91. Pérez-Calvo J, Bernal M, Giraldo P, et al (2000) Co-morbidity in Gaucher’s disease results of a nationwide enquiry in Spain. Eur J Med Res 5: 231–235.PubMedGoogle Scholar
  92. Pinkhas J, Djaldetti M, Yaron M (1965) Coincidence of multiple myeloma with Gaucher’s disease. Isr J Med Sci 1: 537–540.PubMedGoogle Scholar
  93. Pratt PW, Kochwa S, Estren S (1968) Immunoglobulin abnormalities in Gaucher’s disease. Report of 16 cases. Blood 31: 633–640.PubMedGoogle Scholar
  94. Rachmilewitz EA, Kornberg A, Acker M (1982) Vitamin E deficiency due to increased consumption in beta-thalassemia and in Gaucher’s disease. Ann N Y Acad Sci 393: 336–347.PubMedGoogle Scholar
  95. Raynor BB (1962) Spinal-cord compression secondary to Gaucher’s disease. Case report. J Neurosurg 19: 902–905.PubMedCrossRefGoogle Scholar
  96. Ruestow PC, Levinson DJ, Catchatourian R, Sreekanth S, Cohen H, Rosenfeld S (1980) Coexistence of IgA myeloma and Gaucher’s disease. Arch Intern Med 140: 1115–1116.PubMedGoogle Scholar
  97. Rymer MM, Kao CC (1974) Pitfalls in the diagnosis of low-back and leg pain. Postgrad Med 56: 76–80.PubMedGoogle Scholar
  98. Sato C, Morgan A, Lang AE, et al (2005) Analysis of the glucocerebrosidase gene in Parkinson’s disease. Mov Disord 20: 367–370.PubMedGoogle Scholar
  99. Shoenfeld Y, Gallant LA, Shaklai M, Livni E, Djaldetti M, Pinkhas J (1982) Gaucher’s disease: a disease with chronic stimulation of the immune system. Arch Pathol Lab Med 106: 388–391.PubMedGoogle Scholar
  100. Shvidel L, Hurwitz N, Shtalrid M, Zur S, Oliver O, Berrebi A (1995) Complex IgA gammopathy in Gaucher’s disease. Leuk Lymphoma 20: 165–168.PubMedGoogle Scholar
  101. Sidransky E (2004) Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab 83: 6–15.PubMedGoogle Scholar
  102. Soffer D, Yamanaka T, Wenger DA, Suzuki K (1980) Central nervous system involvement in adult-onset Gaucher disease. Acta Neuropathol 49: 1–6.PubMedGoogle Scholar
  103. Spitz M, Rozenberg R, Silveira PAA, Barbosa ER (2006) Parkinsonism in type 1 Gaucher’s disease. J Neurol Neurosurg Psychiatry 77: 709–710.PubMedGoogle Scholar
  104. Tanyel MC, Mancano LD (1997) Neurologic findings in vitamin E deficiency. Am Fam Physician 55: 197–201.PubMedGoogle Scholar
  105. Tayebi N, Callahan M, Madike V, et al (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73: 313–321.PubMedGoogle Scholar
  106. Tayebi N, Walker JM, Stubblefield BK, et al (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79: 104–109.PubMedGoogle Scholar
  107. Turesson I, Rausing A (1975) Gaucher’s disease and benign monoclonal gammapathy. A case report with immunofluorescence study of bone marrow and spleen. Acta Med Scand 197: 507–512.PubMedGoogle Scholar
  108. Tylki-Szymanska A, Millat G, Maire I, Czartoryska B (1996) Types I and III Gaucher disease in Poland: incidence of the most common mutations and phenotypic manifestations. Eur J Hum Genet 4: 334–337.PubMedGoogle Scholar
  109. van Royen-Kerkhof A, Poll-The BT, Kleijer WJ, et al (1998) Coexistence of Gaucher disease type 1 and Joubert syndrome. J Med Genet 35: 965–966.PubMedGoogle Scholar
  110. Várkonyi J, Simon Z, Soós K (2002) Gaucher disease type 1 complicated with Parkinson’s syndrome. Haematologia 32: 271–275.PubMedGoogle Scholar
  111. Várkonyi J, Rosenbaum H, Baumann N, et al (2003) Gaucher disease associated with parkinsonism: four further case reports. Am J Med Genet 116A: 348–351.PubMedGoogle Scholar
  112. Vellodi A, Bembi B, De Villemeur TB, et al (2001) Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 24: 319–327.PubMedGoogle Scholar
  113. Winkelman MD, Banker BQ, Victor M, Moser HW (1983) Non-infantile neuronopathic Gaucher’s disease: a clinicopathologic study. Neurology 33: 994–1008.PubMedGoogle Scholar
  114. Wong K, Sidransky E, Verma A, et al (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 82: 192–207.PubMedGoogle Scholar
  115. Ziegler SG, Eblan MJ, Gutti U, et al (2007) Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 91: 195–200.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • M. Biegstraaten
    • 1
  • I. N. van Schaik
    • 1
  • J. M. F. G. Aerts
    • 2
  • C. E. M. Hollak
    • 3
  1. 1.Department of NeurologyAcademic Medical CentreAmsterdamThe Netherlands
  2. 2.Department of BiochemistryAcademic Medical CentreAmsterdamThe Netherlands
  3. 3.Department of Internal Medicine, Division of Endocrinology and MetabolismAcademic Medical CentreAmsterdamThe Netherlands

Personalised recommendations